Evidence map›Paper›PMID 31383250›Full record

ArticleBMB reports2019

Flrt2 is involved in fine-tuning of osteoclast multinucleation.

Jumpei Shirakawa, Noriko Takegahara, Hyunsoo Kim, Seoung Hoon Lee, Kohji Sato, Satoru Yamagishi, Yongwon Choi

Open access · goldAbstract readNews
In one paragraph

Article in BMB reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Osteoclast Multinucleation: Review of Current Literature.International journal of molecular sciences · 2020
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Jumpei ShirakawaDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Noriko TakegaharaDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Hyunsoo KimDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
Seoung Hoon LeeDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Oral Microbiology and Immunology, College of Dentistry, Wonkwang University, Iksan 54538, Korea.
Kohji SatoDepartment of Organ and Tissue Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan.
Satoru YamagishiDepartment of Organ and Tissue Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka 431-3192, Japan.
Yongwon ChoiDepartment of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
University of Pennsylvania · USHamamatsu University School of Medicine · JPWonkwang University · KR

Funding

Overall: Resource-based Center for Musculoskeletal Disorders Research (Overall Application)P30AR069619 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI LOUIS J SOSLOWSKY · 2016 to 2026
$9.1M
Cell Adhesion Regulation of Osteoclast MaturationR01AR069546 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI CHOI, YONGWON · 2016 to 2020
$1.8M
Molecular regulation of osteoclast maturationR01AR067726 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI CHOI, YONGWON · 2015 to 2018
$1.4M
NIAMS NIH HHS P30 AR069619NIAMS NIH HHS R01 AR067726NIAMS NIH HHS R01 AR069546
6 · The paper itself

Abstract

Osteoclasts are multinucleated giant cells derived from myeloid progenitors. Excessive bone resorption by osteoclasts can result in serious clinical outcomes for which better treatment options are needed. Here, we identified fibronectin leucine-rich transmembrane protein 2 (Flrt2), a ligand of the Unc5 receptor family for neurons, as a novel target associated with the late/maturation stage of osteoclast differentiation. Flrt2 expression is induced by stimulation with receptor activator of nuclear factor-kB ligand (RANKL). Flrt2 deficiency in osteoclasts results in reduced hyper-multinucleation, which could be restored by RNAi-mediated knockdown of Unc5b. Treatment with Netrin1, another ligand of Unc5b which negatively controls osteoclast multinucleation through down regulation of RANKL-induced Rac1 activation, showed no inhibitory effects on Flrt2-deficient cells. In addition, RANKL-induced Rac1 activation was attenuated in Flrt2-deficient cells. Taken together, these results suggest that Flrt2 regulates osteoclast multinucleation by interfering with Netrin 1-Unc5b interaction and may be a suitable therapeutic target for diseases associated with bone remodeling. [BMB Reports 2019; 52(8): 514-519].

Indexed as

AnimalsMembrane GlycoproteinsMiceMice, KnockoutOsteoclastsFLRT2 protein, mouseMembrane Glycoproteins

Identifiers

PMID31383250
PMCPMC6726208
OpenAlexW2972102851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.